Resolving the VEGF paradox in DKD: VEGFR1 blockade shows promising renoprotection
Listen to this summary
The authors investigate the role of the vascular endothelial growth factor (VEGF) system in the progression of diabetic kidney disease (DKD) and seek to clarify the conflicting data surrounding its modulation. They find that while inhibiting VEGF-A or VEGF receptor 2 worsens kidney damage, blocking VEGF receptor 1 consistently provides renoprotection, suggesting that VEGF receptor 1 inhibition could be a viable therapeutic approach for DKD.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Kidney international
View all →Jun 19, 2026 · Kidney international
A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease
Jun 18, 2026 · Kidney international
What does it mean to win? Interpreting hierarchical kidney outcomes in hypertension trials
Jun 18, 2026 · Kidney international
A potential role for effector T cells with Fc receptors in kidney transplant antibody-mediated rejection
Jun 18, 2026 · Kidney international
Quantitative Serological Detection of NELL1 Autoantibodies in Membranous Nephropathy
Jun 18, 2026 · Kidney international
A cluster randomized controlled trial (GOAL trial) evaluated a comprehensive geriatric assessment for frail older people with chronic kidney disease
Jun 18, 2026 · Kidney international
Non-invasive quantitative assessment of kidney injury using near-infrared autofluorescence imaging
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
